Riding The Tailwind Of Healthtech Through The Pandemic And Beyond
COVID-19 Has Not Put The Brakes On Resurgence Of Health Care, Say Asia-Based VC Investors
VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.
You may also be interested in...
Singapore-based SGInnovate has a unique multi stakeholder business model focused on identifying and funding Deep Tech start-ups. CEO Jui Lim now plans to increase the group’s activity in advanced manufacturing and “wetware” ̶ drugs and diagnostics – as firms increasingly are able to revert to pre-COVID business plans.
Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.
For life sciences investors, the past year has been the busiest period in recent memory, say Goodwin partners Sophie McGrath and David Mardle. But what are the industry's drivers and key investor trends in 2021?